Welcome to our dedicated page for Tema Healthcare AI ETF news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Tema Healthcare AI ETF stock.
Cue Health Inc. news covered the company's healthcare technology business, including diagnostic-enabled care, at-home and point-of-care molecular testing, telehealth services, FDA-related product developments, earnings releases, and governance actions. Recurring updates described its COVID-19 and Mpox diagnostic products, customer categories across public agencies and private-sector healthcare users, and cost-reduction or operational efficiency actions.
Later Cue Health news documented the company's Chapter 7 bankruptcy filing and planned wind down, including the intended sale of assets and creditor-payment process under the Bankruptcy Code.
Cue Health (Nasdaq: HLTH), a leader in healthcare technology, announced management presentations at two major investor conferences. The Cowen 42nd Annual Health Care Conference will take place on March 8, 2022 at 1:30 p.m. Eastern Time. The following day, Morgan Stanley Technology, Media & Telecom Conference will occur on March 9, 2022 at 4:15 p.m. Eastern Time in San Francisco. Interested investors can access the live webcasts and 90-day replays on Cue's website.
Summary not available.
Cue Health Inc. (Nasdaq: HLTH) has partnered with Cardinal Health (NYSE: CAH) to expand distribution of its COVID-19 tests across traditional and non-traditional healthcare settings. This collaboration aims to enhance the availability of Cue's nucleic acid amplification tests, which have shown 97.8% concordance with PCR tests, and the innovative at-home test, the first of its kind to gain Emergency Use Authorization from the FDA. Both professional and OTC/home test kits will be available, supporting healthcare providers’ evolving diagnostic needs.
Cue Health (Nasdaq: HLTH) announced a collaboration with actress Gal Gadot to feature its new health smart device in a Super Bowl® commercial airing on February 13, 2022. The ad aims to position Cue as an essential tool for managing health at home. Cue offers the most accurate at-home COVID-19 test, providing results in 20 minutes via the Cue Health App. To enhance accessibility, the company has reduced prices for Cue+ memberships and COVID-19 tests. Cue Health is expanding its diagnostic offerings, focusing on personalized healthcare solutions.
On February 7, 2022, Cue Health (Nasdaq: HLTH) announced its partnership with Johns Hopkins Medicine (JHM) to provide Cue Health Monitoring Systems and Cue COVID-19 tests. The portable systems will be utilized by JHM's healthcare professionals to enhance employee health management. The Cue COVID-19 test, utilizing molecular nucleic acid amplification technology, delivers lab-quality results to mobile devices within 20 minutes and detects all known COVID-19 variants. Cue also supplies tests to various organizations, including Google and the NBA.
Cue Health (Nasdaq: HLTH) will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022 at 12:30 p.m. ET. The webcast is exclusive for conference attendees. Founded in 2010 and based in San Diego, Cue Health focuses on accessible health information, enabling real-time diagnostics for individuals and healthcare providers. They gained recognition for their pioneering COVID-19 test, the first FDA-authorized at-home molecular diagnostic test. Cue Health holds multiple international regulatory approvals.
Cue Health Inc. (NASDAQ: HLTH) announced preliminary unaudited revenue for Q4 and full year 2021. Q4 revenue was between $188 million and $193 million, up from $13 million in Q4 2020. Full year revenue reached $613 million to $618 million, compared to $23 million in 2020. The company reported cash equivalents of $412 million as of December 31, 2021. Significant partnerships were established, including collaborations with Cardinal Health and McKesson, and Cue expanded diagnostics offerings.
Cue Health (Nasdaq: HLTH) announced it will develop an Omicron-Genotyping COVID-19 test, partnering with the U.S. Department of Health and Human Services' BARDA. This test will enhance existing COVID-19 detection capabilities and is aimed at professional point-of-care settings. The funding from BARDA will expedite development and regulatory approval for a single-plex assay specifically targeting the Omicron variant. Cue's technology ensures accurate results in 20 minutes and has been recognized for its lab-quality diagnostics, benefitting patients and public health.
Cue Health (NASDAQ: HLTH), a healthcare technology firm, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference scheduled for January 11, 2022, at 5:15 p.m. Eastern Time. This presentation will be accessible via a live audio webcast on their website for 30 days post-event. Cue Health focuses on providing lab-quality diagnostics and real-time health information, revolutionizing home health management.
Cue Health (Nasdaq: HLTH) announces its first partnership with Air Canada to provide U.S. passengers access to its accurate molecular COVID-19 self-test. The test meets Canada’s entry requirements and can be purchased along with a portable Cue Cartridge Reader, delivering results in about 20 minutes. This partnership aims to enhance travel convenience and safety for Air Canada's U.S. customers, who can enjoy bilingual services expected in early 2022. Cue’s tests are already widely used in various critical settings and detect COVID-19 variants, including Omicron.